Elion Therapeutics

Name

Elion Therapeutics

Legal name

Elion Therapeutics, Inc.

Website

https://eliontx.com

Company type

Private

Founded year

1955

Operating status

Operating

Headcount range

11–50 employees

Short description

Elion Therapeutics is a clinical-stage biotechnology company developing Turletricin (EL219/SF001), a next-generation polyene antifungal designed as a safer, non-nephrotoxic IV alternative to amphotericin B for treating life-threatening invasive fungal infections in immunocompromised patients.

Ownership category

akta.pro rank

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Revenue: Pre-revenue clinical-stage biotechnology company developing antifungal drug candidate EL219 (SF001/Turletricin). Revenue will be generated from prescription drug sales upon FDA approval, targeting hospital and clinical settings for treatment of invasive fungal infections.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Elion Therapeutics is a clinical-stage biotechnology company developing Turletricin (EL219/SF001), a next-generation polyene antifungal drug designed for IV infusion to treat life-threatening invasive fungal infections. The drug is engineered via rational drug design to preferentially extract fungal ergosterol over human cholesterol, reducing the nephrotoxicity associated with conventional amphotericin B therapy while delivering broad-spectrum activity against Candida, Aspergillus, Cryptococcus, Fusarium, and Coccidioides species.

Product overview

Elion Therapeutics is a biotechnology company developing a single core product: Turletricin (also known as EL219 or SF001), a next-generation polyene antifungal drug. This novel polyene therapy is designed as a safer alternative to amphotericin B, addressing critical unmet needs in treating invasive fungal infections. The product is currently in Phase 2 clinical development and has received FDA QIDP and Fast Track designations.

Differentiator

Problem solved

Functional benefit

Brands

• Turletricin (EL219): Brand name for the company's next-generation polyene antifungal drug candidate SF001/EL219, designed to treat invasive fungal infections with reduced toxicity compared to amphotericin B.
• EL219
• SF001

Products and services

• Turletricin (EL219/SF001) Next-generation polyene antifungal drug candidate for IV infusion targeting invasive fungal infections including invasive aspergillosis, cryptococcosis, invasive fusariosis, and CNS coccidioidomycosis. Designed as a non-nephrotoxic alternative to amphotericin B with broad-spectrum activity and once-weekly dosing potential. Has received FDA QIDP and Fast Track designations for empiric antifungal therapy, invasive aspergillosis, and cryptococcosis.

Quantifiable outcome

• Non-nephrotoxic profile demonstrated in Phase 1 clinical trials
• +2 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• University of IllinoisfoundationalStrategic or Co-development PartnerResearchers at the University of Illinois discovered the 'sponge model' mechanism that enables amphotericin B to extract sterols from cell membranes. This foundational scientific discovery informed the rational drug design approach that led to Elion's development candidate EL219. The technology was published in Nature.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Seres Therapeutics: While not directly in antifungals, Seres is a clinical-stage infectious disease/microbiome company that has applied for and received FDA QIDP and other infectious disease regulatory designations. Its experience navigating similar regulatory pathways and clinical-stage infectious disease development makes it a relevant emerging comparator for Elion's commercialization trajectory.
• Matinas BioPharma Holdings: Matinas is a clinical-stage biotech that has explored antifungal applications leveraging its lipid nanocrystal delivery platform. While its primary programs have shifted, it remains an emerging comparator in the antifungal development space with similar early-stage dynamics.

Broad incumbents

• Astellas Pharma: Astellas markets micafungin (Mycamine), an echinocandin antifungal used for invasive candidiasis and aspergillosis, and has a track record in hospital mycology. As a large pharma with an established antifungal franchise, Astellas is a relevant broad incumbent comparable to Elion's positioning.
• Gilead Sciences: Gilead historically marketed AmBisome, the leading liposomal amphotericin B product, and remains a broad incumbent in hospital antifungals. Its established hospital channel and existing amphotericin franchise make it a key comparable and potential strategic acquirer for differentiated polyene programs like EL219.
• Pfizer: Pfizer markets the triazole antifungal isavuconazole (Cresemba) and acquired Amplyx's fosmanogepix program, making it a broad incumbent in the antifungal space. As a large pharma with established hospital sales infrastructure, Pfizer represents both a competitive threat and a potential acquirer of antifungal-focused assets like Elion's EL219.

Direct peers

• Mycovia Pharmaceuticals: Mycovia developed oteseconazole (Vivjoa) for recurrent vulvovaginal candidiasis and advanced programs in invasive fungal infections. Its antifungal-focused pipeline and clinical-stage profile make it a direct comparable to Elion's positioning around invasive and difficult-to-treat fungal disease.
• Amplyx Pharmaceuticals: Amplyx developed fosmanogepix, a novel antifungal Gwt1 inhibitor targeting invasive fungal infections including aspergillosis and rare molds. Its focus on hard-to-treat invasive fungal infections closely mirrors Elion's therapeutic focus, and following acquisition-related activity it remains a relevant comparable program.
• Basilea Pharmaceutica: Basilea develops and commercializes the antifungal isavuconazole (Cresemba, ex-US) through partnerships and has historically developed other hospital antifungals including echinocandins. Its antifungal-focused pipeline targeting invasive mold and yeast infections makes it a relevant direct comparable to Elion.
• Scynexis: Scynexis developed and commercialized ibrexafungerp (Brexafemme), a first-in-class triterpenoid antifungal approved for vulvovaginal candidiasis with clinical programs in invasive fungal infections. As an antifungal-focused company with overlapping mechanism and indication ambitions, it is a direct comparator to Elion.
• Cidara Therapeutics: Cidara Therapeutics is a clinical-stage biotech developing antifungal therapeutics, including the FDA-approved echinocandin rezafungin (Rezzayo) for candidemia and invasive candidiasis. It is a direct competitor to Elion in the invasive fungal infection space, targeting similar hospital-treated patient populations with novel mechanisms.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/eliontx

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Elion Therapeutics